86 related articles for article (PubMed ID: 20449880)
1. Reevaluating erythropoiesis-stimulating agents.
Kimmel PL; Malozowski S
N Engl J Med; 2010 May; 362(18):1742-3; author reply 1743-4. PubMed ID: 20449880
[No Abstract] [Full Text] [Related]
2. Reevaluating erythropoiesis-stimulating agents.
Cotter DJ
N Engl J Med; 2010 May; 362(18):1743; author reply 1743-4. PubMed ID: 20449881
[No Abstract] [Full Text] [Related]
3. Reevaluating erythropoiesis-stimulating agents.
Kestenbaum B
N Engl J Med; 2010 May; 362(18):1742; author reply 1743-4. PubMed ID: 20445190
[No Abstract] [Full Text] [Related]
4. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia".
Coiffier B
Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359
[No Abstract] [Full Text] [Related]
5. Post transplantation anemia: re-emphasizing the use of erythropoietin.
Jabur WL
Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):104-6. PubMed ID: 21196622
[No Abstract] [Full Text] [Related]
6. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
Moossavi S; Freedman BI
Arch Intern Med; 2009 Jun; 169(12):1100-1. PubMed ID: 19546408
[No Abstract] [Full Text] [Related]
7. Novel erythropoiesis-stimulating agents: a new era in anemia management.
Macdougall IC
Clin J Am Soc Nephrol; 2008 Jan; 3(1):200-7. PubMed ID: 18077782
[TBL] [Abstract][Full Text] [Related]
8. Clarifying the use of erythropoietic agents.
Smith RE
J Support Oncol; 2004; 2(3):200, 202; author reply 202. PubMed ID: 15328822
[No Abstract] [Full Text] [Related]
9. Developments in the therapeutic use of erythropoiesis stimulating agents.
Jelkmann W
Br J Haematol; 2008 May; 141(3):287-97. PubMed ID: 18410567
[TBL] [Abstract][Full Text] [Related]
10. Should erythropoietin treatment in chronic heart failure be haemoglobin targeted?
Kleijn L; de Boer RA; Voors AA
Eur J Heart Fail; 2010 Mar; 12(3):215-6. PubMed ID: 20156936
[No Abstract] [Full Text] [Related]
11. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
12. Erythropoiesis-stimulating agents in cancer.
Arcasoy MO
J Clin Oncol; 2008 Jun; 26(18):3097-8; author reply 3098-100. PubMed ID: 18565902
[No Abstract] [Full Text] [Related]
13. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
Walker RG
Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
[No Abstract] [Full Text] [Related]
14. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
15. CERA: third-generation erythropoiesis-stimulating agent.
Topf JM
Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
[TBL] [Abstract][Full Text] [Related]
16. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
Gascón P
Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
[TBL] [Abstract][Full Text] [Related]
17. The treatment of anemia in chronic kidney disease: understandings in 2006.
Levin A
Curr Opin Nephrol Hypertens; 2007 May; 16(3):267-71. PubMed ID: 17420672
[TBL] [Abstract][Full Text] [Related]
18. Use of erythropoiesis stimulating agents for the treatment of anaemia and related fatigue in a pregnant woman with HbH disease.
Macciò A; Madeddu C; Chessa P; Mantovani G; Galanello R
Br J Haematol; 2009 Aug; 146(3):335-7. PubMed ID: 19466977
[No Abstract] [Full Text] [Related]
19. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
20. Erythropoiesis stimulating agents: a personal journey.
Leyland-Jones B
J Natl Cancer Inst; 2013 Jul; 105(14):999-1001. PubMed ID: 23860202
[No Abstract] [Full Text] [Related]
[Next] [New Search]
